Overall Survival of Patients Receiving Cisplatin or Carboplatin for Primary Metastatic Urothelial Carcinoma of the Bladder: A Contemporary Dutch Nationwide Cohort Study

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

(2021) Thomas Powles et al.   LANCET ONCOLOGY

Restricted mean survival time as a summary measure of time‐to‐event outcome

(2020) Takahiro Hasegawa et al.   PHARMACEUTICAL STATISTICS

Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial

(2020) Matthew D Galsky et al.   LANCET

Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

(2020) Thomas Powles et al.   LANCET ONCOLOGY

Adjusted restricted mean survival times in observational studies

(2019) Sarah C. Conner et al.   STATISTICS IN MEDICINE

EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort†

(2019) J. Alfred Witjes et al.   EUROPEAN UROLOGY

Comparison of Propensity Score Methods and Covariate Adjustment

(2017) Markus C. Elze et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

The performance of different propensity score methods for estimating absolute effects of treatments on survival outcomes: A simulation study

(2016) Peter C Austin et al.   STATISTICAL METHODS IN MEDICAL RESEARCH

Prognostic and predictive factors in patients treated with chemotherapy for advanced urothelial cancer: where do we stand?

(2015) Sebastiano Buti et al.   Future Oncology

Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies

(2015) Peter C. Austin et al.   STATISTICS IN MEDICINE

The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments

(2013) Peter C. Austin   STATISTICS IN MEDICINE

Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma

(2011) M. D. Galsky et al.   ANNALS OF ONCOLOGY

Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986

(2011) Maria De Santis et al.   JOURNAL OF CLINICAL ONCOLOGY

A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy

(2011) Matthew D Galsky et al.   LANCET ONCOLOGY

An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies

(2011) Peter C. Austin   MULTIVARIATE BEHAVIORAL RESEARCH

Interconversion of three measures of performance status: An empirical analysis

(2010) Clement Ma et al.   EUROPEAN JOURNAL OF CANCER